Article
Immunology
Ramil R. Mintaev, Dina V. Glazkova, Olga V. Orlova, Georgiy M. Ignatyev, Alexey S. Oksanich, German A. Shipulin, Elena V. Bogoslovskaya
Summary: Dengue fever is a global health problem, affecting over 100 million people annually. Vaccination is the most effective prevention strategy, but the development of vaccines is hindered by the risk of antibody-dependent enhancement. This article presents the development of an MVA-d34 vaccine against dengue virus, using safe and effective MVA viral vector. The vaccine targets the DIII domains of the envelope protein, which do not cause enhanced infection. Immunized mice generate a humoral response against all four dengue virus serotypes, and their sera have virus-neutralizing activity against dengue serotype 2. The MVA-d34 vaccine shows promise as a candidate vaccine against dengue fever.
Article
Immunology
Yunda Huang, Kelly E. Seaton, Martin Casapia, Laura Polakowski, Stephen C. De Rosa, Kristen Cohen, Chenchen Yu, Marnie Elizaga, Carmen Paez, Maurine D. Miner, Colleen F. Kelley, Janine Maenza, Michael Keefer, Javier R. Lama, Magdalena Sobieszczyk, Susan Buchbinder, Lindsey R. Badenj, Carter Lee, Vineeta Gulati, Faruk Sinangil, David Montefiori, M. Juliana McElrath, Georgia D. Tomaras, Harriet L. Robinsonm, Paul Goepfert
Summary: The HVTN 114 study investigated the impact of late boosting with AIDSVAX B/E on the durability and breadth of vaccine-induced immune responses in participants previously enrolled in HVTN 205. The results showed that late boosting with AIDSVAX, alone or in combination with MVA, led to increased binding antibody responses and T-cell responses even years after the initial vaccination.
Article
Immunology
Ashley C. Beavis, Edmund G. -T. Wee, Belkis M. Akis M. Yildirim, Nicola Borthwick, Biao He, Tomas Hanke
Summary: The primary goal of this study is to expand and enhance the options for inducing protective CD8(+) T cells against HIV-1 and respiratory pathogens. Researchers explored the advantages of using the parainfluenza virus 5 (PIV5) vector to deliver pathogen-derived transgenes in combination with other vaccine methods. They found that the PIV5 vector can be combined with other vaccines to enhance mucosal CD8(+) T cell induction. The results pave the way for using these vectors in HIV-1 and other indications in humans.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Rosamund Chapman, Michiel van Diepen, Nicola Douglass, Tandile Hermanus, Penny L. L. Moore, Anna-Lise Williamson
Summary: The immunogenicity of HIV DNA and MVA vaccines administered in a DDMM regimen could be improved using the PharmaJet Stratis needle-free injection device and formulation of the DNA vaccines with CpG adjuvant.
Article
Immunology
Shaswath S. S. Chandrasekar, Brock A. A. Kingstad-Bakke, Chia-Wei Wu, Yashdeep Phanse, Jorge E. E. Osorio, Adel M. M. Talaat
Summary: Infectious bronchitis (IB) is an acute respiratory disease of chickens caused by avian coronavirus Infectious Bronchitis Virus (IBV). The use of Modified Live Virus (MLV) vaccines can lead to virulence reversion and tissue damage in vaccinated birds. This study demonstrates that a mucosal adjuvant system, QuilA-loaded Chitosan (QAC) nanoparticles encapsulating plasmid vaccine encoding for IBV nucleocapsid (N), is protective against IBV.
Article
Immunology
Michela Falqui, Beatriz Perdiguero, Rocio Coloma, Manuel Albert, Laura Marcos-Villar, Joseph Patrick McGrail, Carlos Oscar S. Sorzano, Mariano Esteban, Carmen Elena Gomez, Susana Guerra
Summary: ISG15 is a protein that plays a critical role in the immune response and has been shown to enhance the immune stimulatory activity of HIV vaccines. It can interact with intracellular proteins via reversible or non-covalent binding, and has the potential to be a relevant component in HIV-1 immunization protocols.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2023)
Article
Medicine, General & Internal
Chelsea McLean, Houreratou Barry, Mark Kieh, Zacchaeus Anywaine, Baimba Tapima Rogers, Seydou Doumbia, Sodiomon B. Sirima, Alimamy Serry-Bangura, Abdoul Habib Beavogui, Auguste Gaddah, Michael Katwere, Jenny Hendriks, Babajide Keshinro, Serge Eholie, Hannah Kibuuka, Stephen B. Kennedy, Omu Anzala, Mohamed Samai, Eric D'Ortenzio, Bailah Leigh, Samba Sow, Rodolphe Thiebaut, Brian Greenwood, Deborah Watson-Jones, Macaya Douoguih, Kerstin Luhn, Cynthia Robinson
Summary: This analysis evaluated the immune response to the two-dose, heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen from multiple African sites. The results showed a strong immune response in participants, regardless of age, at 21/28 days post-dose 2.
Article
Immunology
Elke Jordan, Golam Kabir, Stephanie Schultz, Guenter Silbernagl, Darja Schmidt, Victoria A. Jenkins, Heinz Weidenthaler, Daria Stroukova, Barbara K. Martin, Laurence De Moerlooze
Summary: MVA-BN-RSV vaccination reduces viral load and symptom scores, decreases the number of confirmed infections, and induces humoral and cellular immune responses against respiratory syncytial virus (RSV).
JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Multidisciplinary Sciences
Venkata S. S. Bollimpelli, Pradeep B. J. Reddy, Sailaja Gangadhara, Tysheena P. P. Charles, Samantha L. L. Burton, Gregory K. K. Tharp, Tiffany M. M. Styles, Celia C. C. Labranche, Justin C. C. Smith, Amit A. A. Upadhyay, Anusmita Sahoo, Traci Legere, Ayalnesh Shiferaw, Vijayakumar Velu, Tianwei Yu, Mark Tomai, John Vasilakos, Sudhir P. P. Kasturi, George M. M. Shaw, David Montefiori, Steven E. E. Bosinger, Pamela A. A. Kozlowski, Bali Pulendran, Cynthia A. A. Derdeyn, Eric Hunter, Rama R. R. Amara
Summary: The study found that intradermal administration of a live-attenuated vaccinia-based SHIV vaccine provided protection in female macaques, while intramuscular administration did not. Both routes of vaccination induced similar levels of serum IgG with neutralizing and non-neutralizing activities. Intradermal vaccination induced greater germinal center Tfh and B cell responses, reduced the ratio of Th1 to Tfh cells in blood, and showed lower activation of monocytes and inflammasome compared to intramuscular vaccination.
NATURE COMMUNICATIONS
(2023)
Article
Immunology
Hans de Graaf, Ruth O. Payne, Iona Taylor, Kazutoyo Miura, Carol A. Long, Sean C. Elias, Marija Zaric, Angela M. Minassian, Sarah E. Silk, Lee Li, Ian D. Poulton, Megan Baker, Simon J. Draper, Diane Gbesemete, Nathan J. Brendish, Filipa Martins, Arianna Marini, David Mekhaiel, Nick J. Edwards, Rachel Roberts, Johan Vekemans, Sarah Moyle, Saul N. Faust, Eleanor Berrie, Alison M. Lawrie, Fergal Hill, Adrian V. S. Hill, Sumi Biswas
Summary: This study conducted a clinical trial on transmission blocking vaccines targeting the sexual-stages of the malaria parasite, using two recombinant viral vectored vaccines encoding Pfs25-IMX313 in healthy malaria-naive adults. While the vaccines were immunogenic, they showed weak transmission reducing activity.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Kristen M. Marks, Minhee Kang, Triin Umbleja, Anchalee Avihingsanon, Patcharaphan Sugandhavesa, Andrea L. Cox, Karen Vigil, Hugo Perazzo, Jennifer C. Price, Leolin Katsidzira, Christina Vernon, Beverly Alston-Smith, Kenneth E. Sherman
Summary: In this international study, the HepB-CpG vaccine was effective in generating protective hepatitis B virus antibodies in people with HIV who had not been previously vaccinated. There were no unexpected safety concerns observed.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Biochemistry & Molecular Biology
Luca M. Zaeck, Mart M. Lamers, Babs E. Verstrepen, Theo M. Bestebroer, Martin E. van Royen, Hannelore Gotz, Marc C. Shamier, Leanne P. M. van Leeuwen, Katharina S. Schmitz, Kimberley Alblas, Suzanne van Efferen, Susanne Bogers, Sandra Scherbeijn, Guus F. Rimmelzwaan, Eric C. M. van Gorp, Marion P. G. Koopmans, Bart L. Haagmans, Corine H. GeurtsvanKessel, Rory D. de Vries
Summary: In July 2022, the monkeypox outbreak was declared an international public health emergency. Historic smallpox vaccination and monkeypox virus infection can generate MPXV-neutralizing antibodies, but vaccination with MVA-BN results in lower levels of these antibodies. Further studies are needed to assess the efficacy of the MVA-BN vaccine in at-risk populations.
Article
Multidisciplinary Sciences
Alina Tscherne, Jan Hendrik Schwarz, Cornelius Rohde, Alexandra Kupke, Georgia Kalodimou, Leonard Limpinsel, Nisreen M. A. Okba, Berislav Bosnjak, Inga Sandrock, Ivan Odak, Sandro Halwe, Lucie Sauerhering, Katrin Brosinski, Liangliang Nan, Elke Duell, Sylvia Jany, Astrid Freudenstein, Joerg Schmidt, Anke Werner, Michelle Gellhorn Serra, Michael Kluever, Wolfgang Guggemos, Michael Seilmaier, Clemens-Martin Wendtner, Reinhold Foerster, Bart L. Haahmans, Stephan Becker, Gerd Sutter, Asisa Volz
Summary: The SARS-CoV-2 virus has caused the COVID-19 pandemic, and a recombinant MVA expressing the SARS-CoV-2 spike protein shows promise as a candidate for developing a COVID-19 vaccine.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Immunology
Naif Khalaf Alharbi, Fahad Aljamaan, Haya A. Aljami, Mohammed W. Alenazi, Hind Albalawi, Abdulrahman Almasoud, Fatima J. Alharthi, Esam I. Azhar, Tlili Barhoumi, Mohammad Bosaeed, Sarah C. Gilbert, Anwar M. Hashem
Summary: This study reported the immunogenicity of high-dose MVA-MERS vaccine in mice and camels. The results showed that MVA-MERS vaccine induced strong antibody responses, including neutralizing antibodies, in both mice and camels. These findings contribute to the further development and evaluation of this vaccine as a potential approach to reduce MERS-CoV transmission.
Letter
Medicine, General & Internal
Lucy Deng, Laura K. Lopez, Catherine Glover, Patrick Cashman, Renee Reynolds, Kristine Macartney, Nicholas Wood
Summary: This study utilizes data from Australia's vaccine safety surveillance system to investigate the adverse effects of the modified vaccinia Ankara-Bavarian Nordic vaccine.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Infectious Diseases
Rosa Polo, Xabier Garcia-Albeniz, Carolina Teran, Miguel Morales, David Rial-Crestelo, M. Angeles Garcinuno, Miguel Garcia del Toro, Cesar Hita, Juan Luis Gomez-Sirvent, Luis Buzon, Alberto Diaz de Santiago, Jose Perez Arellano, Jesus Sanz, Pablo Bachiller, Elisa Martinez Alfaro, Vicente Diaz-Brito, Mar Masia, Alicia Hernandez-Torres, Jose M. Guerra, Jesus Santos, Piedad Arazo, Leopoldo Munoz, Jose Ramon Arribas, Pablo Martinez de Salazar, Santiago Moreno, Miguel A. Hernan, Julia Del Amo
Summary: This study evaluated the effectiveness of hydroxychloroquine (HCQ) and Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) as pre-exposure prophylaxis for COVID-19. The results suggest that the use of TDF/FTC and HCQ may have both benefits and risks in preventing COVID-19.
CLINICAL MICROBIOLOGY AND INFECTION
(2023)
Article
Immunology
Lorena Usero, Lorna Leal, Carmen Elena Gomez, Laia Miralles, Elena Aurrecoechea, Ignasi Esteban, Berta Torres, Alexy Inciarte, Beatriz Perdiguero, Mariano Esteban, Felipe Garcia, Montserrat Plana
Summary: Researchers tested a novel HIV therapeutic vaccine using unmodified mRNA (TMEP-B) and mRNA modified by 1-methyl-3'-pseudouridylyl (TMEP-Bmod) that expressed sequences from Gag, Pol, and Nef proteins in transfected monocyte-derived dendritic cells (MDDCs) obtained from HIV-infected patients. In vitro experiments were conducted to test the mRNAs alone and in combination with immunomodulators to enhance HIV-specific cellular immune responses. The combination of mRNAs with immunomodulators increased HIV-specific T-cell responses and the secretion of mediators involved in viral control, suggesting that these mRNA vaccines could potentially achieve a functional cure for HIV patients when combined with Vesatolimod and/or Nivolumab.
Article
Infectious Diseases
Natalia Pallares, Cristian Tebe, Gabriela Abelenda-Alonso, Alexander Rombauts, Isabel Oriol, Antonella F. Simonetti, Alejandro Rodriguez-Molinero, Elisenda Izquierdo, Vicens Diaz-Brito, Gemma Molist, Guadalupe Gomez Melis, Jordi Carratala, Sebastian Videla
Summary: This study aims to compare clinical features and outcomes between patients with and without a therapeutic ceiling of care at hospital admission. The study found that patients with a therapeutic ceiling of care were older, had more comorbidities, and fewer clinical signs at baseline. These patients had a higher incidence of death and complications compared to those without a therapeutic ceiling of care.
INFECTIOUS DISEASES AND THERAPY
(2023)
Article
Infectious Diseases
Ines Suarez-Garcia, Belen Alejos, Victoria Hernando, Laura Vinuela, Mar Vera Garcia, David Rial-Crestelo, Maria Jesus Perez Elias, Helena Albendin Iglesias, Joaquim Peraire, Juan Tiraboschi, Asuncion Diaz, Santiago Moreno, Inma Jarrin
Summary: The study assessed the effectiveness and tolerability of DTG/3TC in treatment-naive and virologically suppressed treatment-experienced individuals. The results showed that 91.4% and 93.8% of treatment-naive individuals achieved viral suppression at 24 and 48 weeks, respectively, after starting DTG/3TC. Among treatment-experienced individuals, 97.4% and 95.5% maintained viral suppression at 24 and 48 weeks, respectively, after switching to DTG/3TC.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)
Article
Infectious Diseases
Seef Abdalla, Alexandra Compagnucci, Yi Zheng, Jean-Marc Treluyer, Yacine Saidi, Jose T. Ramos, Alexandra Coelho, Yoann Riault, Tim R. Cressey, Deborah Hirt
Summary: This study aimed to compare the efficacy and safety of switching virologically suppressed children and adolescents with HIV to a once-daily dual regimen of dolutegravir plus ritonavir-boosted darunavir versus continuing standard ART. The results showed that dolutegravir treatment produced adequate total and unbound concentrations in children and adolescents, similar to those obtained in adults.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)
Article
Immunology
Eva Poveda, Wendy Fitzgerald, Cristina Reglero, Alexandre Perez-Gonzalez, Ana Marino, Hortensia Alvarez, Nieves Valcarce, Josep Maria Llibre, Santiago Moreno Guillen, Maria Angeles Munoz Fernandez, Ezequiel Ruiz-Mateos, Leonid Margolis, Michael M. Lederman, Michael L. Freeman
Summary: Elite controllers (EC) had higher levels of plasma extracellular vesicle (EV)-associated cytokines compared to other people with HIV, and persistent controllers (PC) had higher levels than transient controllers (TC). EV-associated IL-18 could distinguish EC from ART-treated individuals, while EV-associated IL-3 and TRAIL could distinguish PC from TC. Further investigation is needed to understand the role of EV-cytokines in intercellular communication and endogenous control of HIV expression.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Virology
Daniel Sepulveda-Crespo, Maria A. Jimenez-Sousa, Amanda Fernandez-Rodiguez, Maria A. Munoz-Fernandez, Jose Luis Jimenez, Santiago Moreno, Felipe Garcia, Isidoro Martinez, Jose M. Benito, Norma Rallon, Salvador Resino
Summary: In this retrospective cohort study, we found a significant association between IRF5-TNPO3 polymorphisms and HIV elite control in long-term nonprogressors (LTNPs). Specifically, certain genotypes and the favorable haplotype of IRF5-TNPO3 were associated with HIV elite control.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Surgery
Josep Badia, Nares Arroyo-Garcia, Ana Vazquez, Alexander Almendral, Aina Gomila-Grange, Domenico Fraccalvieri, David Pares, Ana Abad-Torrent, Marta Pascual, Alejandro Solis-Pena, Mireia Puig-Asensio, Miguel Pera, Francesc Gudiol, Enric Limon, Miquel Pujol
Summary: This study investigated the implementation and outcomes of a nationwide care bundle for colorectal surgery. The results showed that the implementation of the care bundle significantly reduced the rate of surgical site infection.
INTERNATIONAL JOURNAL OF SURGERY
(2023)
Article
Medicine, General & Internal
Elena Vazquez-Alejo, Laura Tarancon-Diez, Maria de la Sierra Espinar-Buitrago, Miguel Genebat, Alba Calderon, Guillermo Perez-Cabeza, Esmeralda Magro-Lopez, Manuel Leal, Ma Angeles Munoz-Fernandez
Summary: In hospitalized patients with SARS-CoV-2, immunological activation is reversed during hospitalization but marked exhaustion patterns persist over time. This dysregulation could be a risk factor for reinfection and the development of other pathologies. Additionally, high levels of SARS-CoV-2-specific T-cell response appear to be associated with infection severity.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Pharmacology & Pharmacy
Andrea Rodriguez-Agustin, Victor Casanova, Judith Grau-Exposito, Sonsoles Sanchez-Palomino, Jose Alcami, Nuria Climent
Summary: Tyrosine kinase inhibitors (TKIs) are widely used to treat chronic myeloid leukemia (CML). Dasatinib, a broad-spectrum TKI with off-target effects, has immunomodulatory capabilities that enhance innate immune responses against cancerous and viral-infected cells. Studies have shown that dasatinib expands memory-like natural killer (NK) cells and γδ T cells, which are associated with improved control of CML and HIV infection. Additionally, dasatinib has potential as a senolytic drug by inducing apoptosis in senescent cells. This review examines the virological and immunogenetic factors associated with dasatinib's cytotoxic effects and discusses its therapeutic potential against CML, HIV infection, and aging.
Article
Infectious Diseases
Christien Rondaan, Alessandra Maso, Rares-Mircea Birlutiu, Marta Fernandez Sampedro, Alex Soriano, Vicens Diaz de Brito, Joan Gomez Junyent, Maria Dolores Del Toro, Jochen Gerhard Hofstaetter, Mauro Jose Salles, Jaime Esteban, Marjan Wouthuyzen-Bakker
Summary: This study aimed to investigate the clinical relevance of an isolated positive sonication fluid culture (SFC) in patients who underwent revision surgery of a prosthetic joint. The results showed that cases with a positive SFC had a slightly higher rate of infection during follow-up compared with controls with a negative SFC, but the difference was not statistically significant. Further exploration in larger trials is needed to draw conclusions about the potential benefit of antibiotic treatment in these cases.
CLINICAL MICROBIOLOGY AND INFECTION
(2023)
Article
Geriatrics & Gerontology
M. S. Espinar-Buitrago, L. Tarancon-Diez, E. Vazquez-Alejo, E. Magro-Lopez, M. Genebat, F. Romero-Candau, M. Leal, M. A. Munoz-Fernandez
Summary: This study investigates the effect of Thymosin-alpha-1 on the immune system of people with different levels of thymic function in SARS-CoV2 infection. The results show that Thymosin-alpha-1 can modulate the activation markers of dendritic cells and decrease the production of proinflammatory cytokines by T cells, improving lymphocyte functionality. Therefore, Thymosin-alpha-1 may have potential benefits in the treatment of COVID-19.
Article
Immunology
Moti N. Ramgopal, Antonella Castagna, Charles Cazanave, Vicens Diaz-Brito, Robin Dretler, Shinichi Oka, Olayemi Osiyemi, Sharon Walmsley, James Sims, Giovanni Di Perri, Kenneth Sutton, Denise Sutherland-Phillips, Alessandro Berni, Christine L. Latham, Feifan Zhang, Ronald D'Amico, Miguel Pascual Bernaldez, Rodica Van Solingen-Ristea, Veerle Van Eygen, Parul Patel, Vasiliki Chounta, William R. Spreen, Harmony P. Garges, Kimberly Smith, Jean van Wyk
Summary: This study compares the efficacy of long-acting cabotegravir plus rilpivirine every 2 months with daily bictegravir, emtricitabine, and tenofovir alafenamide for the maintenance of HIV-1 virological suppression. The results show that long-acting cabotegravir plus rilpivirine is as effective as the commonly used daily regimen, with injection site reactions being the main side effect.
Article
Medicine, General & Internal
Javier Martinez-Sanz, Jorge Diaz-alvarez, Marta Rosas, Raquel Ron, Jose Antonio Iribarren, Enrique Bernal, Felix Gutierrez, Andres Ruiz Sancho, Noemi Cabello, Julian Olalla, Santiago Moreno, Sergio Serrano-Villar
Summary: The study suggests that a low CD4/CD8 ratio during HIV treatment is associated with immunosenescence. Data analysis shows that patients with a CD4/CD8 ratio less than 0.3 in the second year of ART have an increased risk of developing SNAEs in the next five years.
Article
Pediatrics
Anna Turkova, Ellen White, Adeodata R. Kekitiinwa, Vivian Mumbiro, Elizabeth Kaudha, Afaaf Liberty, Grace Miriam Ahimbisibwe, Tumelo Moloantoa, Ussanee Srirompotong, Nozibusiso Rejoice Mosia, Thanyawee Puthanakit, Robin Kobbe, Claudia Fortuny, Hajira Kataike, Dickson Bbuye, Sathaporn Na-Rajsima, Alexandra Coelho, Abbas Lugemwa, Mutsa F. Bwakura-Dangarembizi, Nigel Klein, Hilda A. Mujuru, Cissy Kityo, Mark F. Cotton, Rashida A. Ferrand, Carlo Giaquinto, Pablo Rojo, Avy Violari, Diana M. Gibb, ODYSSEY Trial Team
Summary: This study evaluated the neuropsychiatric manifestations in children and adolescents treated with dolutegravir-based treatment compared to alternative antiretroviral therapy. Numerically, more participants in the dolutegravir group reported psychiatric events and suicidal ideation than those in the standard-of-care group, but these differences should be interpreted cautiously in an open-label trial.
LANCET CHILD & ADOLESCENT HEALTH
(2023)